These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. RNAi-based therapeutics and tumor targeted delivery in cancer. Kara G; Calin GA; Ozpolat B Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticle delivery systems for siRNA-based therapeutics. Li J; Xue S; Mao ZW J Mater Chem B; 2016 Nov; 4(41):6620-6639. PubMed ID: 32263517 [TBL] [Abstract][Full Text] [Related]
4. In vivo application of RNA interference: from functional genomics to therapeutics. Lu PY; Xie F; Woodle MC Adv Genet; 2005; 54():117-42. PubMed ID: 16096010 [TBL] [Abstract][Full Text] [Related]
5. Development of new RNAi therapeutics. Liu G; Wong-Staal F; Li QX Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694 [TBL] [Abstract][Full Text] [Related]
6. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies. Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460 [TBL] [Abstract][Full Text] [Related]
7. RNAi-based nanomedicines for targeted personalized therapy. Daka A; Peer D Adv Drug Deliv Rev; 2012 Oct; 64(13):1508-21. PubMed ID: 22975009 [TBL] [Abstract][Full Text] [Related]
8. Current issues of RNAi therapeutics delivery and development. Haussecker D J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131 [TBL] [Abstract][Full Text] [Related]
11. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
12. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Lee JM; Yoon TJ; Cho YS Biomed Res Int; 2013; 2013():782041. PubMed ID: 23844368 [TBL] [Abstract][Full Text] [Related]
13. RNA interference-based therapy and its delivery systems. Chen X; Mangala LS; Rodriguez-Aguayo C; Kong X; Lopez-Berestein G; Sood AK Cancer Metastasis Rev; 2018 Mar; 37(1):107-124. PubMed ID: 29243000 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840 [TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure. Soriano V AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352 [TBL] [Abstract][Full Text] [Related]
16. Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Mizrahy S; Hazan-Halevy I; Dammes N; Landesman-Milo D; Peer D Mol Ther; 2017 Jul; 25(7):1491-1500. PubMed ID: 28392163 [TBL] [Abstract][Full Text] [Related]
17. Nanoparticle Delivery Systems for DNA/RNA and their Potential Applications in Nanomedicine. Shen H; Huang X; Min J; Le S; Wang Q; Wang X; Dogan AA; Liu X; Zhang P; Draz MS; Xiao J Curr Top Med Chem; 2019; 19(27):2507-2523. PubMed ID: 31775591 [TBL] [Abstract][Full Text] [Related]
19. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution. O'Mahony AM; Godinho BM; Cryan JF; O'Driscoll CM J Pharm Sci; 2013 Oct; 102(10):3469-84. PubMed ID: 23893329 [TBL] [Abstract][Full Text] [Related]
20. Nanotechnology strategies to address challenges in topical and cellular delivery of siRNAs in skin disease therapy. Silvestrini AVP; Morais MF; Debiasi BW; Praça FG; Bentley MVLB Adv Drug Deliv Rev; 2024 Apr; 207():115198. PubMed ID: 38341146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]